SCHEMBL5578773

SCHEMBL5578773

C[C@H](CO)NCC(O)C(Cc1ccccc1)OC(N)=O

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.42
MAPK1 P28482 1/20 0.42
BCHE P06276 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
ADRB2 P07550 4/20 0.40
ADRB1 P08588 1/20 0.39
ADRB3 P13945 1/20 0.39
CYP2C19 P33261 2/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
ALDH1A1 P00352 1/20 0.39
THRB P10828 1/20 0.39
CYP2C9 P11712 1/20 0.39
HSD17B10 Q99714 1/20 0.39
SIGMAR1 Q99720 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3356361 1.00 CYP3A4 (0.42) CYP3A4MAPK1BCHENPC1RAB9A
SCHEMBL3350256 1.00 CYP3A4 (0.42) CYP3A4MAPK1BCHENPC1RAB9A
SCHEMBL3356366 1.00 CYP3A4 (0.42) CYP3A4MAPK1BCHENPC1RAB9A
SCHEMBL5578364 1.00 CYP3A4 (0.42) CYP3A4MAPK1BCHENPC1RAB9A
SCHEMBL3350262 1.00 CYP3A4 (0.42) CYP3A4MAPK1BCHENPC1RAB9A
SCHEMBL5930124 0.82 ANPEP (0.46) CYP3A4MAPK1BCHENPC1RAB9A
SCHEMBL28614227 0.82 KDM4E (0.43) CYP3A4MAPK1BCHENPC1RAB9A
SCHEMBL28628361 0.82 KDM4E (0.43) CYP3A4MAPK1BCHENPC1RAB9A
SCHEMBL16912773 0.82 ANPEP (0.46) CYP3A4MAPK1BCHENPC1RAB9A
SCHEMBL28614224 0.82 KDM4E (0.43) CYP3A4MAPK1BCHENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP CYP3A4 2947/4885MAPK1 3409/4885BCHE 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.